When to Order Imaging for Pretreatment Staging of Urothelial Cancer: ACR Appropriateness Decoded
A patient presents with hematuria, and cystoscopy confirms a new diagnosis of urothelial carcinoma of the bladder. The next critical step is accurate staging, which dictates the entire treatment pathway, from local therapy to systemic chemotherapy and major surgery. Deciding between CT urography, MR urography, or a standard CT of the abdomen and pelvis can be complex, especially when considering radiation dose and the specific clinical question. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the most effective imaging for initial staging of urothelial cancer.
What Does ACR Pretreatment Staging of Urothelial Cancer Cover?
This ACR guideline provides evidence-based recommendations for the initial, pretreatment staging of urothelial cancer in adults. It is organized into three primary clinical scenarios that cover the most common presentations of the disease. The recommendations are designed to help clinicians evaluate the local extent of the primary tumor, assess for regional lymph node involvement, and detect distant metastatic disease.
The scope of this topic specifically includes:
- Staging for non-muscle invasive bladder cancer (NMIBC)
- Staging for muscle-invasive bladder cancer (MIBC)
- Staging for upper urinary tract urothelial cancer (UTUC)
This guideline does not cover imaging for cancer screening, post-treatment surveillance, or the evaluation of other genitourinary malignancies like renal cell carcinoma or prostate cancer. It is focused exclusively on the initial workup after a confirmed diagnosis of urothelial cancer.
What Imaging Should I Order for Pretreatment Staging of Urothelial Cancer? Recommendations by Clinical Scenario
The optimal imaging strategy for urothelial cancer depends heavily on the location and depth of tumor invasion. The ACR provides distinct recommendations for non-muscle invasive, muscle-invasive, and upper tract disease.
For an adult with nonmuscle invasive bladder cancer, the primary goal is to evaluate the upper urinary tracts for synchronous tumors, which can occur. For this reason, both CT Urography (CTU) without and with IV contrast and MR Urography (MRU) without and with IV contrast are rated Usually appropriate. These studies provide detailed visualization of the renal pelves, ureters, and bladder. A standard CT abdomen and pelvis with IV contrast is also Usually appropriate. For local staging of the primary bladder tumor, MRI of the pelvis without and with IV contrast is also Usually appropriate, offering excellent soft tissue resolution to assess for subtle muscle invasion. Pelvic ultrasound may be appropriate but is less definitive for staging.
When the diagnosis is muscle invasive bladder cancer, the need for comprehensive local and distant staging is paramount. Consequently, the list of appropriate studies expands. CTU without and with IV contrast remains a cornerstone and is Usually appropriate for evaluating the entire urinary tract and abdomen. Similarly, MRU without and with IV contrast is an excellent non-ionizing alternative. To assess for metastatic disease, CT chest with IV contrast and a standard chest radiograph are both Usually appropriate. For detecting distant metastases, particularly in nodes or bone, FDG-PET/CT from skull base to mid-thigh is also Usually appropriate. For local pelvic staging, MRI of the pelvis without and with IV contrast is highly valuable.
For an adult with known upper urinary tract urothelial cancer (in the renal pelvis or ureter), imaging must characterize the primary tumor and search for metastases. The definitive study is CTU without and with IV contrast, which is rated Usually appropriate. It is essential for defining the lesion, assessing for hydronephrosis, and evaluating the contralateral kidney and bladder for other lesions. MRU without and with IV contrast is a strong alternative. Systemic staging with a CT chest with IV contrast or a chest radiograph is also Usually appropriate to rule out pulmonary metastases, the most common site of distant spread.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Adult. Nonmuscle invasive bladder cancer. Pretreatment staging. | CTU without and with IV contrast | Usually appropriate | ☢ ☢ ☢ ☢ 10-30 mSv | ☢ ☢ ☢ ☢ ☢ 10-30 mSv [ped] |
| Adult. Nonmuscle invasive bladder cancer. Pretreatment staging. | MRU without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Muscle invasive bladder cancer. Pretreatment staging. | CTU without and with IV contrast | Usually appropriate | ☢ ☢ ☢ ☢ 10-30 mSv | ☢ ☢ ☢ ☢ ☢ 10-30 mSv [ped] |
| Adult. Muscle invasive bladder cancer. Pretreatment staging. | FDG-PET/CT skull base to mid-thigh | Usually appropriate | ☢ ☢ ☢ ☢ 10-30 mSv | ☢ ☢ ☢ ☢ 3-10 mSv [ped] |
| Adult. Muscle invasive bladder cancer. Pretreatment staging. | MRI abdomen and pelvis without and with IV contrast | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Adult. Upper urinary tract urothelial cancer. Pretreatment staging. | CTU without and with IV contrast | Usually appropriate | ☢ ☢ ☢ ☢ 10-30 mSv | ☢ ☢ ☢ ☢ ☢ 10-30 mSv [ped] |
| Adult. Upper urinary tract urothelial cancer. Pretreatment staging. | CT chest with IV contrast | Usually appropriate | ☢ ☢ ☢ 1-10 mSv | ☢ ☢ ☢ ☢ 3-10 mSv [ped] |
Adult vs. Pediatric Pretreatment Staging of Urothelial Cancer Imaging: Radiation Dose Tradeoffs
While urothelial cancer is exceedingly rare in the pediatric population, the principles of staging still apply. The primary difference in imaging considerations is the heightened emphasis on the As Low As Reasonably Achievable (ALARA) principle to minimize cumulative lifetime radiation exposure. For any given CT scan, the relative radiation level (RRL) category is often higher for a pediatric patient than for an adult receiving a similar radiation dose, reflecting the increased radiosensitivity of developing tissues.
Because of this, non-ionizing modalities like MRI and MR Urography are strongly preferred in younger patients when they can provide the necessary diagnostic information. These studies are rated Usually appropriate across multiple scenarios and carry a relative radiation level of zero. When CT is unavoidable for its superior spatial resolution or speed, protocols should be aggressively optimized to reduce the dose to the pediatric patient. The decision to use an ionizing radiation-based study like CT or PET/CT in a child or adolescent requires a careful weighing of the diagnostic benefit against the long-term risks.
Imaging Protocol Details for Pretreatment Staging of Urothelial Cancer
Once you’ve decided on the right study, the specific imaging protocol is critical for obtaining diagnostic-quality images. Our protocol guides provide detailed, scannable instructions on patient preparation, contrast administration, imaging phases, and reconstruction parameters for the key studies recommended in this guideline.
Tools to Help You Order the Right Study
Navigating imaging guidelines and protocols can be challenging. GigHz offers a suite of reference tools designed to support clinical decision-making and streamline the ordering process.
Imaging Appropriateness Selector
For clinical questions beyond urothelial cancer staging, this tool provides a searchable interface to the complete ACR guidelines. It helps you quickly find evidence-based recommendations for hundreds of clinical variants, ensuring you are always ordering the right test for your patient’s specific situation.
Imaging Protocol Library
This library contains detailed, step-by-step protocols for a wide range of CT, MRI, and ultrasound examinations. Use it to understand the technical details of the studies you order, from contrast timing in a CTU to the specific sequences used in a pelvic MRI for bladder cancer staging.
Radiation Dose Calculator
This tool helps you estimate and track cumulative radiation exposure for your patients. It’s an invaluable resource for communicating with patients about the risks and benefits of medical imaging and for adhering to the ALARA principle, especially in younger patients or those requiring frequent scans.
Why is CT Urography (CTU) so often recommended for urothelial cancer?
CT Urography is a specialized CT protocol designed to evaluate the entire urinary tract. It includes multiple imaging phases: a non-contrast phase to detect calcifications and stones, a nephrographic phase to assess the renal parenchyma, and a delayed (excretory) phase where contrast fills the collecting systems, ureters, and bladder. This comprehensive approach is ideal for detecting and characterizing urothelial tumors, which often appear as filling defects in the excretory phase, while also providing excellent anatomic detail for staging.
When should I choose MR Urography (MRU) over CTU?
MR Urography is the preferred alternative to CTU in several situations. The most common reasons are to avoid ionizing radiation, particularly in young patients or those undergoing repeated imaging, and in patients with a severe allergy to iodinated contrast media. MRU provides excellent soft-tissue contrast and, with gadolinium, can offer functional information. While it can be more time-consuming and susceptible to motion artifacts, it is a powerful, non-ionizing tool for evaluating the urinary tract.
Is a PET/CT necessary for all urothelial cancer staging?
No. According to the ACR criteria, FDG-PET/CT is Usually appropriate for staging muscle-invasive bladder cancer, where the risk of distant metastatic disease is significant. It is highly sensitive for detecting nodal and visceral metastases. However, for non-muscle invasive bladder cancer, the risk of metastasis is very low, and FDG-PET/CT is considered Usually not appropriate as its yield is minimal and does not justify the radiation exposure and cost.
What is the difference between a standard CT Abdomen/Pelvis with contrast and a CTU?
A standard CT Abdomen/Pelvis with IV contrast is typically performed with a single imaging acquisition in the portal venous phase (around 60-70 seconds after contrast injection). This is excellent for evaluating solid organs like the liver and spleen, and for general abdominal pathology. A CT Urography (CTU) is a multi-phase study that includes a pre-contrast scan and, most importantly, a delayed excretory phase scan (5-15 minutes post-injection). This delayed phase is crucial for opacifying the ureters and bladder with contrast, allowing for the detection of subtle urothelial lesions that would be missed on a standard single-phase scan.
Does a negative staging scan mean the cancer is confined to the bladder or ureter?
A negative staging scan is reassuring and indicates the absence of macroscopic (visible) metastatic disease. However, it cannot rule out microscopic disease. The primary role of staging imaging is to guide initial therapy—for example, to determine if a patient is a candidate for curative-intent surgery or if they require systemic chemotherapy first. All patients with urothelial cancer, even with negative staging scans, require long-term surveillance due to the risk of local recurrence and metachronous tumors elsewhere in the urinary tract.
Frequently Asked Questions
Why is CT Urography (CTU) so often recommended for urothelial cancer?
CT Urography is a specialized CT protocol designed to evaluate the entire urinary tract. It includes multiple imaging phases: a non-contrast phase to detect calcifications and stones, a nephrographic phase to assess the renal parenchyma, and a delayed (excretory) phase where contrast fills the collecting systems, ureters, and bladder. This comprehensive approach is ideal for detecting and characterizing urothelial tumors, which often appear as filling defects in the excretory phase, while also providing excellent anatomic detail for staging.
When should I choose MR Urography (MRU) over CTU?
MR Urography is the preferred alternative to CTU in several situations. The most common reasons are to avoid ionizing radiation, particularly in young patients or those undergoing repeated imaging, and in patients with a severe allergy to iodinated contrast media. MRU provides excellent soft-tissue contrast and, with gadolinium, can offer functional information. While it can be more time-consuming and susceptible to motion artifacts, it is a powerful, non-ionizing tool for evaluating the urinary tract.
Is a PET/CT necessary for all urothelial cancer staging?
No. According to the ACR criteria, FDG-PET/CT is Usually appropriate for staging muscle-invasive bladder cancer, where the risk of distant metastatic disease is significant. It is highly sensitive for detecting nodal and visceral metastases. However, for non-muscle invasive bladder cancer, the risk of metastasis is very low, and FDG-PET/CT is considered Usually not appropriate as its yield is minimal and does not justify the radiation exposure and cost.
What is the difference between a standard CT Abdomen/Pelvis with contrast and a CTU?
A standard CT Abdomen/Pelvis with IV contrast is typically performed with a single imaging acquisition in the portal venous phase (around 60-70 seconds after contrast injection). This is excellent for evaluating solid organs like the liver and spleen, and for general abdominal pathology. A CT Urography (CTU) is a multi-phase study that includes a pre-contrast scan and, most importantly, a delayed excretory phase scan (5-15 minutes post-injection). This delayed phase is crucial for opacifying the ureters and bladder with contrast, allowing for the detection of subtle urothelial lesions that would be missed on a standard single-phase scan.
Does a negative staging scan mean the cancer is confined to the bladder or ureter?
A negative staging scan is reassuring and indicates the absence of macroscopic (visible) metastatic disease. However, it cannot rule out microscopic disease. The primary role of staging imaging is to guide initial therapy—for example, to determine if a patient is a candidate for curative-intent surgery or if they require systemic chemotherapy first. All patients with urothelial cancer, even with negative staging scans, require long-term surveillance due to the risk of local recurrence and metachronous tumors elsewhere in the urinary tract.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026
